![](/img/cover-not-exists.png)
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Crowley, Jeffrey, Thaçi, Diamant, Joly, Pascal, Peris, Ketty, Papp, Kim A., Goncalves, Joana, Day, Robert M., Chen, Rongdean, Shah, Kamal, Ferrándiz, Carlos, Cather, Jennifer C.Language:
english
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2017.01.052
Date:
April, 2017
File:
PDF, 367 KB
english, 2017